ClinicalTrials.gg
CompletedNCT03567577Updated May 14, 2025

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

A Phase 2 interventional study of Solnatide 25 mg powder for reconstitution for solution for inhalation and 0.9% Saline Solution in ARDS, sponsored by Apeptico Forschung und Entwicklung GmbH. Completed at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Apeptico Forschung und Entwicklung GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase IIb, randomized, placebo-controlled, double-blind, dose escalation study will assess the local and systemic safety of 7 days orally inhaled sequential multiple ascending doses of solnatide in patients with pulmonary permeability oedema and moderate-to-severe ARDS and review potential efficacy endpoints for a future phase III pivotal trial.

02

Conditions studied

  • ARDS

Keywords

  • Peptide
03

In context

Lead sponsor

Apeptico Forschung und Entwicklung GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age.
  2. Patient has been admitted to an ICU, is mechanically ventilated (according to the ventilation and weaning protocol in Appendix I) and stable in this condition for at least 8 hours.
  3. Moderate-to-severe ARDS diagnosis as defined by the Berlin Definition:

    • Onset of ARDS within 1 week of a known clinical insult or new or worsening respiratory symptoms.
    • Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules.
    • Respiratory failure not fully explained by cardiac failure or fluid overload (origin of oedema).
    • PaO2/FiO2 ≤ 200 mm Hg with Positive End-Expiratory Pressure (PEEP) ≥5 cm H2O.
  4. ARDS diagnosis not older than 48 hours.
  5. Extravascular lung water index (EVLWI) ≥ 10 ml/PBW as assessed with a validated bedside measurement (single indicator transpulmonary thermodilution measurement with the PiCCO® system).
  6. Patient who meets criteria for extensive hemodynamic monitoring as per international intensive care medicine standards.
  7. For patients that are temporarily unable to consent (e.g. comatose patients) a subsequent informed consent has to be provided.
  8. Male and Female () patients using adequate .

Exclusion criteria

Exclusion Criteria:

  1. History of allergies or idiosyncrasies to solnatide.
  2. Known use of any other or non-registered drug within 30 days prior to study enrolment.
  3. Severe state of septic shock with a Mean Arterial Pressure (MAP) ≤ 65 mm Hg and a serum lactate level > 4 mmol/L (36 mg/dL) despite adequate volume resuscitation.
  4. An underlying clinical condition that, in the opinion of the Investigator, would make it very unlikely for the patient to be successfully weaned from ventilation due to severe underlying diseases (e.g. severe malnutrition, severe neurological diseases, pulmonary fibrosis or ).
  5. Extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support. In no way are patients to be denied or delayed these procedures to avoid exclusion from the study.
  6. \< 0.3 x 109/L.
  7. Cancer treatment (chemotherapy or biological) or therapy with other agents for organ transplantation within 2 weeks.
  8. Cachexia ( \< 18.5 kg/m2).
  9. Cardiogenic pulmonary oedema diagnosed by echocardiography or pulmonary artery catheter.
  10. Severe skin burns involving more than 15% of body surface.
  11. Subjects who are extremely unlikely to survive more than 48 hours due to the acute conditions of the patient in the opinion of the Investigator.
  12. Subjects transferred from a hospital not participating in this study who are already planned to be re-transferred during the observation period.
  13. Subjects who are not expected to survive the next month because of an underlying uncorrectable medical condition or a do not resuscitate order.
  14. Women known to be pregnant, lactating or having a positive or indeterminate pregnancy test.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Solnatide 5mg

    Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered

    Drug: Solnatide 25 mg powder for reconstitution for solution for inhalation

  • Experimental
    Solnatide 60mg

    Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered

    Drug: Solnatide 25 mg powder for reconstitution for solution for inhalation

  • Experimental
    Solnatide 125mg

    Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered

    Drug: Solnatide 25 mg powder for reconstitution for solution for inhalation

  • Placebo comparator
    Placebo

    0,9% saline solution

    Drug: 0.9% Saline Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Safety endpoint: Any cause death

    Primary Safety Endpoint: Composite endpoint including any cause death at day 28

    Time frame: Randomisation - day 28

  2. Safety endpoint: Drug-related adverse events

    Primary Safety Endpoint: Composite endpoint including drug-related adverse events through day 14

    Time frame: Randomisation - day 14

  3. Safety endpoint: All adverse events

    Primary Safety Endpoint: Composite endpoint including all adverse events through day 28

    Time frame: Randomisation - day 28

Secondary outcomes

  1. EVLWI

    Change in extravascular lung water index (EVLWI) as assessed with a validated bedside measurement (measurement with the PiCCO® system)

    Time frame: baseline - day 7

  2. PVPI

    Change in pulmonary vascular permeability index (PVPI) as assessed with a validated bedside measurement (measurement with the PiCCO® system)

    Time frame: baseline - day 7

  3. Change of ventilatory settings

    Composite endpoint including ventilation mode, ventilation pressures (ventilatory plateau pressure, positive end expiratory pressure, peak inspiratory pressure, mean airway pressure, peak airway pressure, driving pressure), tidal volume

    Time frame: baseline - day 14

  4. Murray lung injury score

    Murray lung injury score is composed of four components: 1) chest radiograph; 2) hypoxaemia score; 3) PEEP and 4) static compliance of respiratory system. The values of the total score may range from 0 to 4. Lower values indicate a better outcome.

    Time frame: baseline - day 7

  5. Oxygenation ratio (PaO2 / FiO2 ratio)

    Time frame: baseline - day 7

  6. Time to extubation

    Time frame: baseline - day 28

  7. Ventilator-free days (VFD)

    Time frame: baseline - day 28

  8. Days of hospitalization and in ICU

    Time frame: baseline - day 28

07

Study locations

15 sites
  • Univ.-klinik f. Herz-, Thorax-, Gefäßchirurgische Anästhesiologie und lntensivmedizin, Medizinische Universität Graz
    Graz, Steiermark 8036, Austria
  • Univ. Klinik für Innere Medizin / Gem. Einrichtung für Intensiv- und Notfallmedizin/GE Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
  • Department of Anesthesia, General Intensive Care and Pain Control,Medical University of Vienna
    Vienna, 1090, Austria
  • Klinik für Anaesthesiologie, Klinikum der Universität München, Campus Großhadern
    München, Bayern 81377, Germany
  • Klinik für Operative Intensivmedizin und Intermediate Care
    Aachen, Nordrhein-Westfalen 52074, Germany
  • Klinik und Poliklinik für Anästhesiologie und Intensivtherapie / Universitätsklinikum Carl Gustav Carus
    Dresden, Sachsen 01307, Germany
  • Universitätsklinikum Bonn, Operative Intensivmedizin, Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin
    Bonn, 53127, Germany
  • Georg-August-Universität Göttingen
    Göttingen, 37075, Germany
  • Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Schleswig-Holstein, Campus Kiel,
    Kiel, 24105, Germany
  • Klinik für Anästhesiologie / Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Klinik für Anästhesiologie und operative Intensivmedizin; Universitätsmedizin Mannheim
    Mannheim, 68167, Germany
  • Klinik für Anästhesiologie und Intensivmedizin; Klinikum rechts der Isar der TU München
    München, 81675, Germany
  • Klinik und Poliklinik für Innere Medizin II; Klinikum rechts der Isar der TU München
    München, 81675, Germany
  • Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie; Universitätsklinikum Münster
    Münster, 48149, Germany
  • Universitätsklinikum Würzburg, Klinik und Poliklinik für Anästhesiologie
    Würzburg, 97080, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Dec 2024, 79 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2018
First posted
Jun 26, 2018
StartActual
May 23, 2018
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03567577
Lead sponsor
Apeptico Forschung und Entwicklung GmbH
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
May 23, 2018
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Last update
May 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP301 peptide

Start the discussion